New drug cocktail hopes to tackle tough lung cancer
NCT ID NCT07232849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing a new drug called HRS-4508, given as a tablet, together with other anticancer drugs (SHR-A1811 and/or Adebrelimab) in 100 adults with advanced non-small cell lung cancer that has not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the combination shrinks tumors. Researchers will also monitor how long any benefit lasts and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4508 tablet combined with other anticancer drugs (SHR-A1811 and/or Adebrelimab)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer who have not responded to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The combination drugs may cause side effects, and it is not yet known if they will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200430, China
Contact
-
Zhejiang Tumor Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact